Lifevantage price to book ratio LFVN

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026: 2.2×
10-year median: 3.8×
Against its 10-year history: 20th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.3× to 15.6×
Peer median: 1.5×

Lifevantage's price to book ratio is 2.2× as of Oct 23, 2026.

That is below its ten-year median of 3.8×, lower than on 80% of days in the last ten years.

Over that time it ranged from 1.3× in Apr 2023 to 15.6× in Dec 2016.

The median for 8 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

median 3.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.2×	1.6×	3.8×
2025	2.3×	2.3×	11.4×
2024	8.1×	2.5×	8.1×
2023	2.6×	1.3×	2.9×
2022	1.5×	1.4×	2.3×
2021	2.2×	2.2×	4.0×
2020	3.9×	3.9×	8.1×
2019	7.3×	5.9×	10.8×
2018	7.8×	3.1×	8.5×
2017	4.3×	3.1×	7.7×
2016	8.1×	8.1×	25.6×
2015	29.1×	14.7×	32.4×
2014	18.5×	3.6×	57.0×
2013	4.7×	4.4×	9.3×
2012	6.9×	6.6×	40.5×

Against its peers

Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first, today.

Company	Price to book ratio
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
ATNMActinium Pharmaceuticals	1.6×
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
Peer median	1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Lifevantage

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.